These results collectively demonstrate that USP20 enhances lung metastasis and EMT in vivo by upregulating CTSL expression, and that pharmacologic inhibition of USP20 may serve as a promising therapeutic strategy for CTSL‐driven cancers. This evidence concerns the gene USP20 and cancer.